semaglutide
Why Obesity Treatment Stalls-GLP-1 Drugs Deliver
In 2023, tirzepatide cut major cardiovascular events by 70% in a large outcomes study, showing that GLP-1 therapies can reverse the dead-end most patients hit with traditional weight-loss plans. The drug’s dual-action mechanism, once-weekly dosing, and tolerable side-effect profile make it a practical bridge from diet-only attempts to lasting